Prognosis of Small Cell Lung Cancer

Prognostic factors are defined as the pre-therapeutic factors characterizing a patient (or his/her disease) that are related to clinical outcomes of the disease. Ideally, using prognostic factors should make it possible to make predictions about patient outcomes, either individually or on a collective level, in order to construct patient classifications that exemplify homogeneity with respect to the prognosis inside the classes and heterogeneity between groups.

[1]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[2]  B. Rapoport,et al.  Small cell lung cancer: analysis of factors influencing the response to treatment and survival. , 1994, Oncology.

[3]  J. Lafitte,et al.  Long-term survivors of small-cell lung cancer (SCLC): A French multicenter study , 1997 .

[4]  D. Caillaud,et al.  [Chemotherapy of small cell bronchial cancers. Prognostic importance of complete response (1,280 patients). Groupe Petites Cellules]. , 1995, Presse medicale.

[5]  J. Watine.  Laboratory Variables as Additional Staging Parameters in Patients with Small-Cell Lung Carcinoma. A Systematic Review , 1999, Clinical chemistry and laboratory medicine.

[6]  N. Saijo,et al.  Prognostic factors and prognostic staging system for small cell lung cancer. , 1997, Japanese journal of clinical oncology.

[7]  I. Smith,et al.  Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. , 1987, European journal of cancer & clinical oncology.

[8]  T. Soussi,et al.  Serum p53 antibodies: predictors of survival in small-cell lung cancer? , 2000, British Journal of Cancer.

[9]  J. Crowley,et al.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Kiura,et al.  Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group Trials. , 1998, Acta medica Okayama.

[11]  D. Spiegelman,et al.  Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Ginsberg,et al.  Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Souhami,et al.  Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. , 1990, British Journal of Cancer.

[14]  O. Brodin,et al.  Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis , 1990, Cancer.

[15]  J. Muir,et al.  Chimiothérapie des cancers bronchiques à petites cellules. Importance pronostique d'une réponse complète (1,280 patients). Groupe Petites Cellules. , 1995 .

[16]  J. Aparicio,et al.  Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Pujol,et al.  Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. , 1998, Cancer detection and prevention.

[18]  R. Souhami,et al.  Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. , 1985, Cancer research.

[19]  U Sagman,et al.  Small-cell carcinoma of the lung: derivation of a prognostic staging system. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Cottin,et al.  Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Giampietro Gasparini,et al.  Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .

[22]  P. Andersen,et al.  Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. , 1986, Cancer research.

[23]  H. Bünemann,et al.  Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. , 1995, International journal of radiation oncology, biology, physics.

[24]  R. Stephens,et al.  A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. , 1993, British Journal of Cancer.

[25]  D. Payne,et al.  The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Crowley,et al.  Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. , 1991, Chest.

[27]  P. Andersen,et al.  Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. George.  Identification and assessment of prognostic factors. , 1988, Seminars in oncology.

[29]  V. Ninane,et al.  Prognostic factors for patients with small cell lung carcinoma , 2000, Cancer.

[30]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[31]  P. Harper,et al.  Predictive and prognostic factors in small cell lung cancer: current status. , 2000, Lung cancer.

[32]  S. Steinberg,et al.  Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Verdebout,et al.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.

[34]  V. Bramwell,et al.  Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients , 1987, International journal of cancer.

[35]  P. Andersen,et al.  Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer. , 1987, Cancer research.

[36]  R. Simon.  Importance of prognostic factors in cancer clinical trials. , 1984, Cancer treatment reports.

[37]  P. Johnson,et al.  Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. , 1996, British Journal of Cancer.

[38]  H. Hansen,et al.  Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Arriagada,et al.  Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy , 1998, Cancer.

[40]  A. Zwinderman,et al.  Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma , 1998, Journal of Cancer Research and Clinical Oncology.

[41]  S. Love,et al.  Prognosis at presentation of small cell carcinoma of the lung. , 1990, European journal of cancer.

[42]  N. Malats,et al.  Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. , 1997, Journal of the National Cancer Institute.

[43]  Maurer Lh,et al.  Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. , 1981 .

[44]  R. Stephens,et al.  Long-term survival in small cell lung cancer: the case for a standard definition , 1996 .

[45]  N. Malats,et al.  Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Holle,et al.  Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. , 1991, British Journal of Cancer.

[47]  A. Purohit,et al.  Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. , 2000, Lung cancer.

[48]  K. Østerlind,et al.  Chromogranin A, a significant prognostic factor in small cell lung cancer , 1999, British Journal of Cancer.